“Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery”
SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off. This marks the first time in recent years that the Company has organized an event specifically focused on pharmaceutical R&D innovation. The forum focused on LNP- and extracellular vesicle-based drug delivery systems covering topics such as development trend,...
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
CASTRES, France and CAMBRIDGE, England, Sept. 25, 2023 /PRNewswire/ -- Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets. Under the terms of the agreement, Vernalis will use its expertise to enable...
‘Bayer For Her’ Supporting 365 Days Conversations of Care to More Women in Asia
Bridging the gap on lack of discussion amongst Asian women on their health concerns this World Contraception Day (WCD) SINGAPORE, Sept. 25, 2023 /PRNewswire/ -- Bayer Pharmaceuticals Division in Asia/Pacific announced today in conjunction with World Contraception Day, the inception of its 'Bayer For Her' regional campaign that has been...
ASTRAZENECA AND INSTITUT KANSER NEGARA PARTNER TO INTRODUCE AI TECHNOLOGY FOR LUNG SCREENING
The partnership paves the way for the adoption of AI technology in chest x-ray for early lung screening at government health facilities KUALA LUMPUR, Malaysia, Sept. 22, 2023 /PRNewswire/ -- In conjunction with Institut Kanser Negara's (IKN) 10th anniversary, AstraZeneca announced its collaboration to accelerate digitalisation in healthcare by introducing Artificial Intelligence (AI) x-ray technology into early lung screening...
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD
SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders, today announced that China's National Medical Products Administration has approved AffaMed's Clinical Trial Application (CTA) to investigate the efficacy and safety of...
Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs containing fluorouracil and platinum for the first-line treatment of patients with PD-L1 positive unresectable locally advanced/recurrent or metastatic esophageal squamous...
MediLink Therapeutics: Focuses on ADC research and development to promote new prospects for cancer treatment
----- YL201 Phase I/II Investigators Meeting was successfully held in Guangzhou, China GUANGZHOU, China, Sept. 23, 2023 /PRNewswire/ -- On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered in Guangzhou to participate in the YL201 Phase I/II Investigators Meeting hosted by Suzhou MediLink Therapeutics Co., Ltd. The chair of this meeting was...
Concord Medical Reports Financial Results for the First Half of 2023
BEIJING, Sept. 23, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six...
Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility
SALT LAKE CITY, Sept. 22, 2023 /PRNewswire/ -- Biomerics, the leading vertically integrated medical device contract manufacturer in the interventional device market, announced the completion of a 100,000-square-foot expansion of their operations in Brooklyn Park, Minnesota, bringing the facility to a total size of 170,000 square feet. Driven by increased demand, this investment benefits customers by consolidating multiple facilities...
Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development
Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein drug. Chime Biologics will provide development and manufacturing services to Panolos Bioscience for PB203, a next-generation immuno-oncology drug. WUHAN, China and HWASEONG-SI, South Korea, Sept. 22, 2023 /PRNewswire/ -- Chime Biologics, a leading CDMO that enables biologic therapeutics development announced...
